Wang X - Search Results

1

ROS-mediated anticancer effects of EGFR-targeted nanoceria.

Johnson KK, Koshy P, Kopecky C, Devadason M, Biazik J, Zheng X, Jiang Y, Wang X, Liu Y, Holst J, Yang JL, Kilian KA, Sorrell CC. Johnson KK, et al. Among authors: wang x. J Biomed Mater Res A. 2024 May;112(5):754-769. doi: 10.1002/jbm.a.37656. Epub 2023 Dec 12. J Biomed Mater Res A. 2024. PMID: 38084898

2

Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence.

Wang X, Goldstein D, Crowe PJ, Yang JL. Wang X, et al. Onco Targets Ther. 2016 Sep 6;9:5461-73. doi: 10.2147/OTT.S94745. eCollection 2016. Onco Targets Ther. 2016. PMID: 27660463 Free PMC article. Review.

3

Antitumour effects and mechanisms of action of the panHER inhibitor, dacomitinib, alone and in combination with the STAT3 inhibitor, S3I-201, in human sarcoma cell lines.

Wang X, Goldstein D, Crowe PJ, Yang JL. Wang X, et al. Int J Oncol. 2018 Jun;52(6):2143-2154. doi: 10.3892/ijo.2018.4337. Epub 2018 Mar 27. Int J Oncol. 2018. PMID: 29620166

4

Geometrically Structured Microtumors in 3D Hydrogel Matrices.

Molley TG, Wang X, Hung TT, Jayathilaka PB, Yang JL, Kilian KA. Molley TG, et al. Among authors: wang x. Adv Biosyst. 2020 May;4(5):e2000056. doi: 10.1002/adbi.202000056. Epub 2020 Apr 8. Adv Biosyst. 2020. PMID: 32402124

5

Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma.

Wang X, Goldstein D, Crowe PJ, Yang M, Garrett K, Zeps N, Yang JL. Wang X, et al. Oncotarget. 2016 Apr 19;7(16):21496-509. doi: 10.18632/oncotarget.7452. Oncotarget. 2016. PMID: 26909593 Free PMC article.

6

Geometric regulation of histone state directs melanoma reprogramming.

Lee J, Molley TG, Seward CH, Abdeen AA, Zhang H, Wang X, Gandhi H, Yang JL, Gaus K, Kilian KA. Lee J, et al. Among authors: wang x. Commun Biol. 2020 Jul 3;3(1):341. doi: 10.1038/s42003-020-1067-1. Commun Biol. 2020. PMID: 32620903 Free PMC article.

7

The synergistic inhibitory effect of combining therapies targeting EGFR and mitochondria in sarcomas.

Wang X, Yeo RX, Hogg PJ, Goldstein D, Crowe P, Dilda PJ, Yang JL. Wang X, et al. Oncotarget. 2020 Jan 7;11(1):46-61. doi: 10.18632/oncotarget.27416. eCollection 2020 Jan 7. Oncotarget. 2020. PMID: 32002123 Free PMC article.

8

Impact of STAT3 inhibition on survival of osteosarcoma cell lines.

Wang X, Goldstein D, Crowe PJ, Yang JL. Wang X, et al. Anticancer Res. 2014 Nov;34(11):6537-45. Anticancer Res. 2014. PMID: 25368256

9

STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review).

Wang X, Crowe PJ, Goldstein D, Yang JL. Wang X, et al. Int J Oncol. 2012 Oct;41(4):1181-91. doi: 10.3892/ijo.2012.1568. Epub 2012 Jul 24. Int J Oncol. 2012. PMID: 22842992 Review.

10

Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines.

Lim HJ, Wang X, Crowe P, Goldstein D, Yang JL. Lim HJ, et al. Among authors: wang x. Anticancer Res. 2016 Nov;36(11):5765-5771. doi: 10.21873/anticanres.11160. Anticancer Res. 2016. PMID: 27793898

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

193,476 results

Search Page